Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Drug-induced Anaphylaxis

Author(s): Marina Labella, Rocío Saénz de Santa María, Gádor Bogas, María Salas, Tahía D. Fernández, Cristobalina Mayorga, Maria José Torres* and Inmaculada Doña

Volume 29, Issue 3, 2023

Published on: 27 October, 2022

Page: [196 - 208] Pages: 13

DOI: 10.2174/1381612829666221024154951

Price: $65

Abstract

Drug hypersensitivity is increasing worldwide as the consumption of drug is increasing. Many clinical presentations of drug hypersensitivity are complex and take place in the setting of illness and/or polypharmacotherapy. To review the most recent findings in the diagnosis and management of immediate drug hypersensitivity reactions. Studies were selected based on their relevance, originality and date of publication. The understanding of endotypes, biomarkers and phenotypes has improved the categorization of immediate hypersensitivity reactions. In this review, we discussed the short- and long-term management of anaphylaxis with a special focus on in vivo and in vitro diagnostic methods. Moreover, the clinical management of drug-induced anaphylaxis, the role of hidden allergens and the importance of delabeling are discussed. Endophenotyping is crucial to correctly diagnose and treat patients with immediate drug hypersensitivity reactions, preventing future episodes through drug desensitization.

« Previous Next »
[1]
Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 2020; 145(4): 1082-123.
[http://dx.doi.org/10.1016/j.jaci.2020.01.017] [PMID: 32001253]
[2]
Johansson SGO, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113(5): 832-6.
[http://dx.doi.org/10.1016/j.jaci.2003.12.591] [PMID: 15131563]
[3]
Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: Summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117(2): 391-7.
[http://dx.doi.org/10.1016/j.jaci.2005.12.1303] [PMID: 16461139]
[4]
Huang F, Chawla K, Järvinen KM. Nowak-Węgrzyn A. Anaphylaxis in a New York City pediatric emergency department: Triggers, treatments, and outcomes. J Allergy Clin Immunol 2012; 129(1): E3.
[http://dx.doi.org/10.1016/j.jaci.2011.09.018] [PMID: 22018905]
[5]
Liew WK, Williamson E, Tang MLK. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 2009; 123(2): 434-42.
[http://dx.doi.org/10.1016/j.jaci.2008.10.049] [PMID: 19117599]
[6]
Rangkakulnuwat P, Sutham K, Lao-Araya M. Anaphylaxis: Tenyear retrospective study from a tertiary-care hospital in Asia. Asian Pac J Allergy Immunol 2020; 38(1): 31-9.
[PMID: 30447654]
[7]
Beyer K, Eckermann O, Hompes S, Grabenhenrich L, Worm M. Anaphylaxis in an emergency setting - elicitors, therapy and incidence of severe allergic reactions. Allergy 2012; 67(11): 1451-6.
[http://dx.doi.org/10.1111/all.12012] [PMID: 23004029]
[8]
Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: Temporal patterns and demographic associations. J Allergy Clin Immunol 2014; 134(6): 1318-1328.e7.
[http://dx.doi.org/10.1016/j.jaci.2014.08.018] [PMID: 25280385]
[9]
Wong A, Seger DL, Lai KH, Goss FR, Blumenthal KG, Zhou L. Drug hypersensitivity reactions documented in electronic health records within a large health system. J Allergy Clin Immunol Pract 2019; 7(4): 1253-1260.e3.
[http://dx.doi.org/10.1016/j.jaip.2018.11.023] [PMID: 30513361]
[10]
Klein JS, Yocum MW. Underreporting of anaphylaxis in a community emergency room. J Allergy Clin Immunol 1995; 95(2): 637-8.
[http://dx.doi.org/10.1016/S0091-6749(95)70329-2] [PMID: 7852677]
[11]
Kaufman DW, de Latorre FJ, Laszlo A, et al. Risk of anaphylaxis in a hospital population in relation to the use of various drugs: An international study. Pharmacoepidemiol Drug Saf 2003; 12(3): 195-202.
[http://dx.doi.org/10.1002/pds.822] [PMID: 12733472]
[12]
Moro MM, Alonso TMA, Hernández EJ, García MMVM, Ingelmo RA, Vila Albelda C. Incidence of anaphylaxis and subtypes of anaphylaxis in a general hospital emergency department. J Investig Allergol Clin Immunol 2011; 21(2): 142-9.
[PMID: 21462805]
[13]
Yocum MW, Butterfield JH, Klein JS, Volcheck GW, Schroeder DR, Silverstein MD. Epidemiology of anaphylaxis in Olmsted county: A population-based study. J Allergy Clin Immunol 1999; 104(2 I): 452-6.
[14]
Dhopeshwarkar N, Sheikh A, Doan R, et al. Drug-induced anaphylaxis documented in electronic health records. J Allergy Clin Immunol Pract 2019; 7(1): 103-11.
[http://dx.doi.org/10.1016/j.jaip.2018.06.010] [PMID: 29969686]
[15]
Castells M. Diagnosis and management of anaphylaxis in precision medicine. J Allergy Clin Immunol 2017; 140(2): 321-33.
[http://dx.doi.org/10.1016/j.jaci.2017.06.012] [PMID: 28780940]
[16]
Kuruvilla M, Khan DA. Anaphylaxis to drugs. Immunol Allergy Clin North Am 2015; 35(2): 303-19.
[http://dx.doi.org/10.1016/j.iac.2015.01.008] [PMID: 25841553]
[17]
Romano A, Guéant-Rodriguez RM, Viola M, Pettinato R, Guéant JL. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann Intern Med 2004; 141(1): 16-22.
[http://dx.doi.org/10.7326/0003-4819-141-1-200407060-00010] [PMID: 15238366]
[18]
Dwyer DF, Barrett NA, Austen KF. Expression profiling of constitutive mast cells reveals a unique identity within the immune system. Nat Immunol 2016; 17(7): 878-87.
[http://dx.doi.org/10.1038/ni.3445] [PMID: 27135604]
[19]
Asselin B. Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia. Future Oncol 2016; 12(13): 1609-21.
[http://dx.doi.org/10.2217/fon-2016-0005] [PMID: 27086555]
[20]
Broyles AD, Banerji A, Castells M. Practical guidance for the evaluation and management of drug hypersensitivity: General concepts. J Allergy Clin Immunol Pract 2020; 8(9): S3-S15.
[http://dx.doi.org/10.1016/j.jaip.2020.08.002] [PMID: 32791249]
[21]
Picard M, Pur L, Caiado J, et al. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol 2016; 137(4): 1154-1164.e12.
[http://dx.doi.org/10.1016/j.jaci.2015.10.039] [PMID: 26725998]
[22]
Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: Cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract 2013; 1(5): 494-500.
[http://dx.doi.org/10.1016/j.jaip.2013.06.002] [PMID: 24565621]
[23]
Descotes J, Choquet-Kastylevsky G. Gell and Coombs’s classification: Is it still valid? Toxicology 2001; 158(1-2): 43-9.
[http://dx.doi.org/10.1016/S0300-483X(00)00400-5] [PMID: 11164991]
[24]
Muraro A, Lemanske RF, Castells M, Torres MJ, Khan D, Simon HU, et al. Precision medicine in allergic disease—food allergy, drug allergy, and anaphylaxis—practall document of the European academy of allergy and clinical immunology and the American academy of allergy, asthma and immunology. Allergy Eur J Allergy Clin Immunol 2017; 72: 1006-21.
[25]
Muñoz-Cano R, Picado C, Valero A, Bartra J. Mechanisms of anaphylaxis beyond IgE. J Investig Allergol Clin Immunol 2016; 26(2): 73-82.
[http://dx.doi.org/10.18176/jiaci.0046] [PMID: 27164622]
[26]
Jimenez-Rodriguez T, Garcia-Neuer M, Alenazy LA, Castells M. Anaphylaxis in the 21st century: Phenotypes, endotypes, and biomarkers. J Asthma Allergy 2018; 11: 121-42.
[http://dx.doi.org/10.2147/JAA.S159411] [PMID: 29950872]
[27]
Labella M, Garcia-Neuer M, Castells M. Application of precision medicine to the treatment of anaphylaxis. Curr Opin Allergy Clin Immunol 2018; 18(3): 190-7.
[http://dx.doi.org/10.1097/ACI.0000000000000435] [PMID: 29601357]
[28]
Doña I, Pérez-Sánchez N, Salas M, et al. Clinical characterization and diagnostic approaches for patients reporting hypersensitivity reactions to quinolones. J Allergy Clin Immunol Pract 2020; 8(8): 2707-2714.e2.
[http://dx.doi.org/10.1016/j.jaip.2020.04.051] [PMID: 32376487]
[29]
Doña I, Blanca-López N, Boteanu C, et al. Clinical practice guidelines for diagnosis and management of hypersensitivity reactions to quinolones. J Investig Allergol Clin Immunol 2021; 31(4): 292-307.
[http://dx.doi.org/10.18176/jiaci.0669] [PMID: 33461956]
[30]
Simons F. 9. Anaphylaxis. J Allergy Clin Immunol 2008; 121(2): S402-7.
[http://dx.doi.org/10.1016/j.jaci.2007.08.061] [PMID: 18241691]
[31]
Brown SGA. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114(2): 371-6.
[http://dx.doi.org/10.1016/j.jaci.2004.04.029] [PMID: 15316518]
[32]
Isabwe GAC, Garcia Neuer M, de las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. J Allergy Clin Immunol 2018; 142(1): 159-170.e2.
[http://dx.doi.org/10.1016/j.jaci.2018.02.018] [PMID: 29518427]
[33]
Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 309(8009): 466-9.
[http://dx.doi.org/10.1016/S0140-6736(77)91953-5] [PMID: 65572]
[34]
Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002; 57(1): 45-51.
[PMID: 11991289]
[35]
Sloane D, Govindarajulu U, Harrow-Mortelliti J, et al. Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract 2016; 4(3): 497-504.
[http://dx.doi.org/10.1016/j.jaip.2015.12.019] [PMID: 26895621]
[36]
Torres J, Romano A, Mayorga C, et al. Diagnostic evaluation of a large group of patients with immediate allergy to penicillins: The role of skin testing. Allergy 2001; 56(9): 850-6.
[http://dx.doi.org/10.1034/j.1398-9995.2001.00089.x] [PMID: 11551249]
[37]
Sousa-Pinto B, Tarrio I, Blumenthal KG, et al. Accuracy of penicillin allergy diagnostic tests: A systematic review and meta-analysis. J Allergy Clin Immunol 2021; 147(1): 296-308.
[http://dx.doi.org/10.1016/j.jaci.2020.04.058] [PMID: 32446963]
[38]
Broyles AD, Banerji A, Barmettler S, et al. Practical guidance for the evaluation and management of drug hypersensitivity: Specific drugs. J Allergy Clin Immunol Pract 2020; 8(9): S16-S116.
[http://dx.doi.org/10.1016/j.jaip.2020.08.006] [PMID: 33039007]
[39]
Özdemir KS, Yilmaz I, Aydin Ö, et al. Immediate-type hypersensitivity reactions to proton pump inhibitors: Usefulness of skin tests in the diagnosis and assessment of cross-reactivity. Allergy 2013; 68(8): 1008-14.
[40]
Aranda A, Mayorga C, Ariza A, et al. In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones. Allergy 2011; 66(2): 247-54.
[http://dx.doi.org/10.1111/j.1398-9995.2010.02460.x] [PMID: 20722637]
[41]
Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy 2015; 70(11): 1393-405.
[http://dx.doi.org/10.1111/all.12698] [PMID: 26198455]
[42]
Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, et al. In vitro tests for drug hypersensitivity reactions: An ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2016; 71: 1103-34.
[43]
Sanz ML, Gamboa PM, Antépara I, et al. Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. Clin Exp Allergy 2002; 32(2): 277-86.
[http://dx.doi.org/10.1046/j.1365-2222.2002.01305.x] [PMID: 11929494]
[44]
Torres MJ, Padial A, Mayorga C, et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. Clin Exp Allergy 2004; 34(11): 1768-75.
[http://dx.doi.org/10.1111/j.1365-2222.2004.02110.x] [PMID: 15544603]
[45]
Torres MJ, Ariza A, Mayorga C, et al. Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions. J Allergy Clin Immunol 2010; 125(2): 502-505.e2.
[http://dx.doi.org/10.1016/j.jaci.2009.11.032] [PMID: 20159266]
[46]
Salas M, Laguna JJ, Doña I, et al. Patients taking amoxicillin-clavulanic can become simultaneously sensitized to both drugs. J Allergy Clin Immunol Pract 2017; 5(3): 694-702.e3.
[http://dx.doi.org/10.1016/j.jaip.2017.02.007] [PMID: 28342830]
[47]
Sánchez-Morillas L, Pérez-Ezquerra PR, Reaño-Martos M, Laguna-Martínez JJ, Sanz ML, Martínez LM. Selective allergic reactions to clavulanic acid: A report of 9 cases. J Allergy Clin Immunol 2010; 126(1): 177-9.
[http://dx.doi.org/10.1016/j.jaci.2010.03.012] [PMID: 20434202]
[48]
Eberlein B, Suárez IL, Darsow U, Ruëff F, Behrendt H, Ring J. A new basophil activation test using CD63 and CCR3 in allergy to antibiotics. Clin Exp Allergy 2010; 40(3): 411-8.
[http://dx.doi.org/10.1111/j.1365-2222.2009.03426.x] [PMID: 20082620]
[49]
De Week AL, Sanz ML, Gamboa PM, et al. Diagnosis of immediate-type beta-lactam allergy in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: A multicenter study. J Investig Allergol Clin Immunol 2009; 19(2): 91-109.
[PMID: 19476013]
[50]
Abuaf N, Rostane H, Barbara J, et al. Comparison of CD63 upregulation induced by nsaids on basophils and monocytes in patients with NSAID hypersensitivity. J Allergy 2012; 2012: 1-9.
[http://dx.doi.org/10.1155/2012/580873] [PMID: 22187572]
[51]
Romano A, Atanaskovic-Markovic M, Barbaud A, et al. Towards a more precise diagnosis of hypersensitivity to beta‐lactams — an EAACI position paper. Allergy 2020; 75(6): 1300-15.
[http://dx.doi.org/10.1111/all.14122] [PMID: 31749148]
[52]
Uyttebroek AP, Sabato V, Cop N, et al. Diagnosing cefazolin hypersensitivity: Lessons from dual-labeling flow cytometry. J Allergy Clin Immunol Pract 2016; 4(6): 1243-5.
[http://dx.doi.org/10.1016/j.jaip.2016.08.016] [PMID: 27836066]
[53]
Bogas G, Doña I, Dionicio J, et al. Diagnostic approach of hypersensitivity reactions to cefazolin in a large prospective cohort. J Allergy Clin Immunol Pract 2021; 9(12): 4421-4430.e4.
[http://dx.doi.org/10.1016/j.jaip.2021.08.017] [PMID: 34464750]
[54]
Rouzaire P, Nosbaum A, Denis L, et al. Negativity of the basophil activation test in quinolone hypersensitivity: A breakthrough for provocation test decision-making. Int Arch Allergy Immunol 2012; 157(3): 299-302.
[http://dx.doi.org/10.1159/000328211] [PMID: 22041525]
[55]
Ebo DG, Bridts CH, Hagendorens MM, Mertens CH, De Clerck LS, Stevens WJ. Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. Allergy 2006; 61(8): 935-9.
[http://dx.doi.org/10.1111/j.1398-9995.2006.01094.x] [PMID: 16867045]
[56]
Gamboa PM, García-Avilés MC, Urrutia I, Antépara I, Esparza R, Sanz ML. Basophil activation and sulfidoleukotriene production in patients with immediate allergy to betalactam antibiotics and negative skin tests. J Investig Allergol Clin Immunol 2004; 14(4): 278-83.
[PMID: 15736712]
[57]
Gómez E, Blanca-Lopez N, Torres MJ, et al. Immunogloblin E-mediated immediate allergic reactions to dipyrone: Value of basophil activation test in the identification of patients. Clin Exp Allergy 2009; 39(8): 1217-24.
[http://dx.doi.org/10.1111/j.1365-2222.2009.03237.x] [PMID: 19400910]
[58]
Ariza A, Fernandez TD, Doña I, et al. Basophil activation after nonsteroidal anti-inflammatory drugs stimulation in patients with immediate hypersensitivity reactions to these drugs. Cytometry A 2014; 85(5): 400-7.
[http://dx.doi.org/10.1002/cyto.a.22443] [PMID: 24443418]
[59]
Salas M, Gomez F, Fernandez TD, et al. Diagnosis of immediate hypersensitivity reactions to radiocontrast media. Allergy 2013; 68(9): 1203-6.
[http://dx.doi.org/10.1111/all.12214]
[60]
Pinnobphun P, Buranapraditkun S, Kampitak T, Hirankarn N, Klaewsongkram J. The diagnostic value of basophil activation test in patients with an immediate hypersensitivity reaction to radiocontrast media. Ann Allergy Asthma Immunol 2011; 106(5): 387-93.
[http://dx.doi.org/10.1016/j.anai.2010.12.020] [PMID: 21530870]
[61]
Trcka J, Schmidt C, Seitz CS, Bröcker EB, Gross GE, Trautmann A. Anaphylaxis to iodinated contrast material: Nonallergic hypersensitivity or IgE-mediated allergy? Am J Roentgenol 2008; 190(3): 666-70.
[http://dx.doi.org/10.2214/AJR.07.2872] [PMID: 18287437]
[62]
Giavina-Bianchi P, Galvão VR, Picard M, Caiado J, Castells MC. Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy. J Allergy Clin Immunol Pract 2017; 5(3): 728-36.
[http://dx.doi.org/10.1016/j.jaip.2016.11.006] [PMID: 28034549]
[63]
Fernández TD, Torres MJ, Blanca-López N, et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Allergy 2009; 64(2): 242-8.
[http://dx.doi.org/10.1111/j.1398-9995.2008.01713.x] [PMID: 19178404]
[64]
Kvedariene V, Kamey S, Ryckwaert Y, et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Allergy 2006; 61(3): 311-5.
[http://dx.doi.org/10.1111/j.1398-9995.2006.00978.x] [PMID: 16436139]
[65]
Mayorga C, Andreu I, Aranda A, et al. Fluoroquinolone photodegradation influences specific basophil activation. Int Arch Allergy Immunol 2013; 160(4): 377-82.
[http://dx.doi.org/10.1159/000343023] [PMID: 23183272]
[66]
Fernández TD, Ariza A, Palomares F, et al. Hypersensitivity to fluoroquinolones. Medicine 2016; 95(23): e3679.
[http://dx.doi.org/10.1097/MD.0000000000003679] [PMID: 27281069]
[67]
MacGlashan D Jr. Expression of CD203c and CD63 in human basophils: Relationship to differential regulation of piecemeal and anaphylactic degranulation processes. Clin Exp Allergy 2010; 40(9): 1365-77.
[http://dx.doi.org/10.1111/j.1365-2222.2010.03572.x] [PMID: 20633031]
[68]
Mayorga C, Ebo DG, Lang DM, et al. Controversies in drug allergy: In vitro testing. J Allergy Clin Immunol 2019; 143(1): 56-65.
[http://dx.doi.org/10.1016/j.jaci.2018.09.022] [PMID: 30573343]
[69]
Laguna JJ, Bogas G, Salas M, et al. The basophil activation test can be of value for diagnosing immediate allergic reactions to omeprazole. J Allergy Clin Immunol Pract 2018; 6(5): 1628-1636.e2.
[http://dx.doi.org/10.1016/j.jaip.2017.12.001] [PMID: 29339127]
[70]
Fontaine C, Mayorga C, Bousquet PJ, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate? -lactam allergy. Allergy 2007; 62(1): 47-52.
[http://dx.doi.org/10.1111/j.1398-9995.2006.01268.x] [PMID: 17156341]
[71]
Blanca M, Mayorga C, Torres MJ, et al. Clinical evaluation of Pharmacia CAP Systemtm RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy. Allergy 2001; 56(9): 862-70.
[http://dx.doi.org/10.1034/j.1398-9995.2001.00995.x] [PMID: 11551251]
[72]
Vultaggio A, Matucci A, Nencini F, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65(5): 657-61.
[http://dx.doi.org/10.1111/j.1398-9995.2009.02280.x] [PMID: 19951375]
[73]
Johansson SGO, Adédoyin J, van Hage M, Grönneberg R, Nopp A. False-positive penicillin immunoassay: An unnoticed common problem. J Allergy Clin Immunol 2013; 132(1): 235-7.
[http://dx.doi.org/10.1016/j.jaci.2012.11.017] [PMID: 23270810]
[74]
Manfredi M, Severino M, Testi S, et al. Detection of specific IgE to quinolones. J Allergy Clin Immunol 2004; 113(1): 155-60.
[http://dx.doi.org/10.1016/j.jaci.2003.09.035] [PMID: 14713922]
[75]
Monneret G, Benoit Y, Debard AL, Gutowski MC, Topenot I, Bienvenu J. Monitoring of basophil activation using CD63 and CCR3 in allergy to muscle relaxant drugs. Clin Immunol 2002; 102(2): 192-9.
[http://dx.doi.org/10.1006/clim.2001.5156] [PMID: 11846462]
[76]
Mata E, Guéant JL, Moneret-Vautrin DA, et al. Clinical evaluation of in vitro leukocyte histamine release in allergy to muscle relaxant drugs. Allergy 1992; 47(5): 471-6.
[http://dx.doi.org/10.1111/j.1398-9995.1992.tb00667.x] [PMID: 1283060]
[77]
Leysen J, Bridts CH, De Clerck LS, et al. Allergy to rocuronium: From clinical suspicion to correct diagnosis. Allergy 2011; 66(8): 1014-9.
[http://dx.doi.org/10.1111/j.1398-9995.2011.02569.x] [PMID: 21375539]
[78]
Ebo DG, Venemalm L, Bridts CH, et al. Immunoglobulin E antibodies to rocuronium: A new diagnostic tool. Anesthesiology 2007; 107(2): 253-9.
[http://dx.doi.org/10.1097/01.anes.0000270735.40872.f2] [PMID: 17667569]
[79]
Laroche D, Chollet-Martin S, Léturgie P, et al. Evaluation of a new routine diagnostic test for immunoglobulin E sensitization to neuromuscular blocking agents. Anesthesiology 2011; 114(1): 91-7.
[http://dx.doi.org/10.1097/ALN.0b013e31820164d2] [PMID: 21169794]
[80]
Rouzaire P, Proton G, Bienvenu F, et al. IgE antibody detection in the diagnosis of hypersensitivity to neuromuscular blocking agents. Acta Anaesthesiol Scand 2012; 56(2): 263-4.
[http://dx.doi.org/10.1111/j.1399-6576.2011.02540.x] [PMID: 22091673]
[81]
Matucci A, Pratesi S, Petroni G, et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 2013; 43(6): 659-64.
[82]
Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med 2008; 358(11): 1109-17.
[http://dx.doi.org/10.1056/NEJMoa074943] [PMID: 18337601]
[83]
Mariotte D, Dupont B, Gervais R, et al. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs 2011; 3(4): 396-401.
[http://dx.doi.org/10.4161/mabs.3.4.16293] [PMID: 21654207]
[84]
Hesterberg PE, Banerji A, Oren E, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management. J Allergy Clin Immunol 2009; 123(6): 1262-1267.e1.
[http://dx.doi.org/10.1016/j.jaci.2009.02.042] [PMID: 19501233]
[85]
Himly M, Jahn-Schmid B, Pittertschatscher K, et al. IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol 2003; 111(4): 882-8.
[http://dx.doi.org/10.1067/mai.2003.163] [PMID: 12704373]
[86]
Harrer A, Lang R, Grims R, et al. Diclofenac hypersensitivity: Antibody responses to the parent drug and relevant metabolites. PLoS One 2010; 5(10): e13707.
[87]
Simons FER, Ebisawa M, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J 2015; 8(1): 32.
[http://dx.doi.org/10.1186/s40413-015-0080-1] [PMID: 26525001]
[88]
Torres MJ, Mayorga C, Cornejo-García JA, Romano A, Blanca M. IgE antibodies to penicillin in skin test negative patients. Allergy 2002; 57(10): 965-5.
[http://dx.doi.org/10.1034/j.1398-9995.2002.23832_10.x] [PMID: 12269955]
[89]
Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: General considerations. Allergy 2003; 58(9): 854-63.
[http://dx.doi.org/10.1034/j.1398-9995.2003.00279.x] [PMID: 12911412]
[90]
Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug allergy. Allergy 2014; 69(4): 420-37.
[http://dx.doi.org/10.1111/all.12350] [PMID: 24697291]
[91]
Doña I, Barrionuevo E, Salas M, et al. NSAIDs-hypersensitivity often induces a blended reaction pattern involving multiple organs. Sci Rep 2018; 8(1): 16710.
[http://dx.doi.org/10.1038/s41598-018-34668-1] [PMID: 30420763]
[92]
Doña I, Blanca-López N, Cornejo-García JA, et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: Patterns of response. Clin Exp Allergy 2011; 41(1): 86-95.
[http://dx.doi.org/10.1111/j.1365-2222.2010.03651.x] [PMID: 21155908]
[93]
Blanca-López N, Bogas G, Doña I, et al. ASA must be given to classify multiple NSAID-hypersensitivity patients as selective or cross-intolerant. Allergy 2016; 71(4): 576-8.
[http://dx.doi.org/10.1111/all.12823] [PMID: 27003105]
[94]
Doña I, Pérez-Sánchez N, Eguiluz-Gracia I, et al. Progress in understanding hypersensitivity reactions to nonsteroidal anti‐inflammatory drugs. Allergy 2020; 75(3): 561-75.
[http://dx.doi.org/10.1111/all.14032] [PMID: 31469167]
[95]
Doña I, Pérez-Sánchez N, Bogas G, Moreno E, Salas M, Torres MJ. Medical algorithm: Diagnosis and treatment of nonsteroidal antiinflammatory drugs hypersensitivity. Allergy 2020; 75(4): 1003-5.
[http://dx.doi.org/10.1111/all.14119] [PMID: 31742729]
[96]
Romano A, Gaeta F, Valluzzi RL, Caruso C, Rumi G, Bousquet PJ. IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol 2010; 126(5): 994-9.
[http://dx.doi.org/10.1016/j.jaci.2010.06.052] [PMID: 20888035]
[97]
Torres MJ, Celik GE, Whitaker P, et al. A EAACI drug allergy interest group survey on how European allergy specialists deal with β-lactam allergy. Allergy Eur J Allergy Clin Immunol 2019; 74(6): 1052-62.
[http://dx.doi.org/10.1111/all.13721]
[98]
Blanca M, Torres MJ, García JJ, et al. Natural evolution of skin test sensitivity in patients allergic to β-lactam antibiotics. J Allergy Clin Immunol 1999; 103(5): 918-24.
[http://dx.doi.org/10.1016/S0091-6749(99)70439-2] [PMID: 10329829]
[99]
Romano A, Gaeta F, Valluzzi RL, Zaffiro A, Caruso C, Quaratino D. Natural evolution of skin-test sensitivity in patients with IgE-mediated hypersensitivity to cephalosporins. Allergy 2014; 69(6): 806-9.
[http://dx.doi.org/10.1111/all.12390] [PMID: 24673580]
[100]
Moreno E, Laffond E, Muñoz-Bellido F, et al. Performance in real life of the European Network on Drug Allergy algorithm in immediate reactions to beta-lactam antibiotics. Allergy 2016; 71(12): 1787-90.
[http://dx.doi.org/10.1111/all.13032] [PMID: 27543745]
[101]
Núñez GI, Villarejo BMJ, Mármol AMA, Aguilar MC, Pasadas GF. Diagnosis of patients with immediate hypersensitivity to beta-lactams using retest. J Investig Allergol Clin Immunol 2012; 22(1): 41-7.
[PMID: 22448453]
[102]
Hershkovich J, Broides A, Kirjner L, Smith H, Gorodischer R. Beta lactam allergy and resensitization in children with suspected beta lactam allergy. Clin Exp Allergy 2009; 39(5): 726-30.
[http://dx.doi.org/10.1111/j.1365-2222.2008.03180.x] [PMID: 19178535]
[103]
Antúnez C, Fernández T, Blanca-Lopez N, et al. IgE antibodies to betalactams: Relationship between the triggering hapten and the specificity of the immune response. Allergy Eur J Allergy Clin Immunol 2006; 61(8): 940-6.
[104]
Lopez-Serrano MC, Caballero MT, Barranco P, Martinez-Alzamora F. Booster responses in the study of allergic reactions to beta-lactam antibiotics. J Investig Allergol Clin Immunol 1996; 6(1): 30-5.
[PMID: 8833166]
[105]
Matheu V, Perez-Rodriguez E, Sanchez-Machin I, Garcia-Robaina JC, De La Torre Morin F. Importance of repeat testing in the diagnosis of penicillin allergy. Br J Dermatol 2006; 154(1): 198-8.
[http://dx.doi.org/10.1111/j.1365-2133.2005.07027.x] [PMID: 16403125]
[106]
Blanca M, Garcia J, Vega JM, et al. Anaphylaxis to penicillins after non-therapeutic exposure: An immunological investigation. Clin Exp Allergy 1996; 26(3): 335-40.
[http://dx.doi.org/10.1111/j.1365-2222.1996.tb00100.x] [PMID: 8729672]
[107]
Torres MJ, Romano A, Celik G, et al. Approach to the diagnosis of drug hypersensitivity reactions: Similarities and differences between Europe and North America. Clin Transl Allergy 2017; 7(1): 7.
[http://dx.doi.org/10.1186/s13601-017-0144-0] [PMID: 28293415]
[108]
Doña I, Romano A, Torres MJ. Algorithm for betalactam allergy diagnosis. Allergy 2019; 74(9): 1817-9.
[http://dx.doi.org/10.1111/all.13844] [PMID: 31034613]
[109]
Torres MJ, Adkinson NF Jr, Caubet JC, et al. Controversies in drug allergy: Beta-lactam hypersensitivity testing. J Allergy Clin Immunol Pract 2019; 7(1): 40-5.
[http://dx.doi.org/10.1016/j.jaip.2018.07.051] [PMID: 30245291]
[110]
Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID‐19 vaccine. Clin Exp Allergy 2021; 51(6): 861-3.
[http://dx.doi.org/10.1111/cea.13874] [PMID: 33825239]
[111]
Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy Eur J Allergy Clin Immunol 2021; 16(11): 3307-13.
[112]
Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA Jr. Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. J Allergy Clin Immunol Pract 2021; 9(8): 2968-82.
[http://dx.doi.org/10.1016/j.jaip.2021.03.002] [PMID: 33737254]
[113]
Bruusgaard-Mouritsen MA, Jensen BM, Poulsen LK, Duus Johansen J, Garvey LH. Optimizing investigation of suspected allergy to polyethylene glycols. J Allergy Clin Immunol 2022; 149(1): 168-175.e4.
[http://dx.doi.org/10.1016/j.jaci.2021.05.020] [PMID: 34052265]
[114]
Stone CA Jr, Liu Y, Relling MV, et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: More common than we have recognized. J Allergy Clin Immunol Pract 2019; 7(5): 1533-1540.e8.
[http://dx.doi.org/10.1016/j.jaip.2018.12.003] [PMID: 30557713]
[115]
Krantz MS, Liu Y, Phillips EJ, Stone CA Jr. Anaphylaxis to PEGylated liposomal echocardiogram contrast in a patient with IgE-mediated macrogol allergy. J Allergy Clin Immunol Pract 2020; 8(4): 1416-1419.e3.
[http://dx.doi.org/10.1016/j.jaip.2019.12.041] [PMID: 31954852]
[116]
Krantz MS, Liu Y, Phillips EJ, Stone CA Jr. COVID‐19 vaccine anaphylaxis: PEG or not? Allergy 2021; 76(6): 1934-7.
[http://dx.doi.org/10.1111/all.14722] [PMID: 34128562]
[117]
Labella M, Céspedes JA, Doña I, et al. The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID‐19 vaccine. Allergy 2022; 77(7): 2067-79.
[118]
Sellaturay P, Nasser S, Ewan P. Polyethylene glycol-induced systemic allergic reactions (Anaphylaxis). J Allergy Clin Immunol Pract 2021; 9(2): 670-5.
[http://dx.doi.org/10.1016/j.jaip.2020.09.029] [PMID: 33011299]
[119]
Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: A review. Clin Exp Allergy 2016; 46(7): 907-22.
[http://dx.doi.org/10.1111/cea.12760] [PMID: 27196817]
[120]
Picard M. Management of hypersensitivity reactions to taxanes. Immunol Allergy Clin North Am 2017; 37(4): 679-93.
[http://dx.doi.org/10.1016/j.iac.2017.07.004] [PMID: 28965634]
[121]
Lukawska J, Mandaliya D, Chan AWE, et al. Anaphylaxis to trometamol excipient in gadolinium-based contrast agents for clinical imaging. J Allergy Clin Immunol Pract 2019; 7(3): 1086-7.
[http://dx.doi.org/10.1016/j.jaip.2018.08.035] [PMID: 30217530]
[122]
Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives—A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy 2020; 75: 2445-76.
[123]
Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020; 75: 1564-81.
[124]
Rodriguez-Coira J, Sokolowska M. SARS‐CoV‐2 candidate vaccines ‐ composition, mechanisms of action and stages of clinical development. Allergy 2021; 76(6): 1922-4.
[http://dx.doi.org/10.1111/all.14714] [PMID: 33340417]
[125]
Sampath V, Rabinowitz G, Shah M, et al. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy 2021; 76: 1640-60.
[126]
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383(27): 2603-15.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]
[127]
Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med 2021; 384(7): 643-9.
[http://dx.doi.org/10.1056/NEJMra2035343] [PMID: 33378605]
[128]
Klimek L, Jutel M, Akdis CA, et al. ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines - An EAACI‐ARIA position paper. Allergy 2021; 76(6): 1624-8.
[http://dx.doi.org/10.1111/all.14726] [PMID: 33378789]
[129]
Pfaar O, Klimek L, Jutel M, et al. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA position paper. Allergy 2021; 76: 648-76.
[130]
Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA 2021; 325(11): 1101-2.
[http://dx.doi.org/10.1001/jama.2021.1967] [PMID: 33576785]
[131]
Troelnikov A, Perkins G, Yuson C, et al. Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in] patients with PEG allergy. J Allergy Clin Immunol 2021; 148(1): 91-5.
[http://dx.doi.org/10.1016/j.jaci.2021.04.032] [PMID: 33991580]
[132]
Cabanillas B, Akdis CA, Novak N. Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol? Allergy 2021; 76(6): 1617-8.
[http://dx.doi.org/10.1111/all.14711] [PMID: 33320974]
[133]
Bianchi L, Biondi F, Hansel K, Murgia N, Tramontana M, Stingeni L. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing. Allergy 2021; 76(8): 2605-7.
[134]
Nilsson L, Brockow K, Alm J, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol 2017; 28(7): 628-40.
[http://dx.doi.org/10.1111/pai.12762] [PMID: 28779496]
[135]
Banerji A, Wickner PG, Saff R, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and suggested approach. J Allergy Clin Immunol 2021; 9(4): 1423-37.
[136]
Sokolowska M, Eiwegger T, Ollert M, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy 2021; 76: 1629-39.
[137]
Krantz MS, Bruusgaard-Mouritsen MA, Koo G, Phillips EJ, Stone CA Jr, Garvey LH. Anaphylaxis to the first dose of mRNA SARS‐CoV‐2 vaccines: Don’t give up on the second dose. Allergy 2021; 76(9): 2916-20.
[http://dx.doi.org/10.1111/all.14958] [PMID: 34028041]
[138]
Cabanillas B, Akdis CA, Novak N. COVID‐19 vaccine anaphylaxis: IgE, complement or what else? A reply to: “COVID‐19 vaccine anaphylaxis: PEG or not?”. Allergy 2021; 76(6): 1938-40.
[http://dx.doi.org/10.1111/all.14725] [PMID: 34128561]
[139]
del Carmen Sancho M, Breslow R, Sloane D, Castells M. Desensitization for hypersensitivity reactions to medications. Chem Immunol Allergy 2012; 97: 217-33.
[http://dx.doi.org/10.1159/000335637] [PMID: 22613865]
[140]
Macy E, Bernstein JA, Castells MC, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: A practice paper. Ann Allergy Asthma Immunol 2007; 98(2): 172-4.
[http://dx.doi.org/10.1016/S1081-1206(10)60692-8] [PMID: 17304886]
[141]
Cahill KN, Laidlaw TM. Pathogenesis of aspirin-induced reactions in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am 2016; 36(4): 681-91.
[http://dx.doi.org/10.1016/j.iac.2016.06.005] [PMID: 27712763]
[142]
Quiralte-Castillo J, Ávila-Castellano MR, Cimbolle KS, et al. Nasal ketorolac challenge using acoustic rhinometry in patients with aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol 2017; 27(3): 169-74.
[http://dx.doi.org/10.18176/jiaci.0118] [PMID: 27758759]
[143]
Lee RU, White AA, Ding D, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2010; 105(2): 130-5.
[http://dx.doi.org/10.1016/j.anai.2010.05.020] [PMID: 20674823]
[144]
Miller B, Mirakian R, Gane S, et al. Nasal lysine aspirin challenge in the diagnosis of aspirin ‐ exacerbated respiratory disease. Clin Exp Allergy 2013; 43(8): 874-80.
[http://dx.doi.org/10.1111/cea.12110] [PMID: 23889241]
[145]
Cook KA, White AA. Rapid aspirin challenge in patients with aspirin allergy and acute coronary syndromes. Curr Allergy Asthma Rep 2016; 16(2): 11.
[http://dx.doi.org/10.1007/s11882-015-0593-2] [PMID: 26758864]
[146]
Sancho-Serra MC, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization. Eur J Immunol 2011; 41(4): 1004-13.
[http://dx.doi.org/10.1002/eji.201040810] [PMID: 21360700]
[147]
de las Vecillas Sánchez L, Alenazy L, Garcia-Neuer M, Castells M. Drug hypersensitivity and desensitizations: Mechanisms and new approaches. Int J Mol Sci 2017; 18(6): 1316.
[http://dx.doi.org/10.3390/ijms18061316] [PMID: 28632196]
[148]
Labella M, Castells M. Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor-monoclonal antibodies and desensitization. Ann Allergy Asthma Immunol 2021; 126(6): 623-9.
[http://dx.doi.org/10.1016/j.anai.2021.03.008] [PMID: 33781937]
[149]
Silver J, Garcia-Neuer M, Lynch DM, Pasaoglu G, Sloane DE, Castells M. Endophenotyping oxaliplatin hypersensitivity: Personalizing desensitization to the atypical platin. J Allergy Clin Immunol Pract 2020; 8(5): 1668-1680.e2.
[http://dx.doi.org/10.1016/j.jaip.2020.02.013] [PMID: 32112926]
[150]
Jakubovic BD, Vecillas L, Jimenez-Rodriguez TW, Sanchez-Sanchez S, Castells M. Drug hypersensitivity in the fast lane. Ann Allergy Asthma Immunol 2020; 124(6): 566-72.
[http://dx.doi.org/10.1016/j.anai.2020.04.005] [PMID: 32302769]
[151]
Gelincik A, Demir S, Şen F, et al. Interleukin-10 is increased in successful drug desensitization regardless of the hypersensitivity reaction type. Asia Pac Allergy 2019; 9(1): e9.
[http://dx.doi.org/10.5415/apallergy.2019.9.e9] [PMID: 30740357]
[152]
Khan DA, Banerji A, Bernstein JA, et al. Cephalosporin allergy: Current understanding and future challenges. J Allergy Clin Immunol Pract 2019; 7(7): 2105-14.
[http://dx.doi.org/10.1016/j.jaip.2019.06.001] [PMID: 31495420]
[153]
Lacombe-Barrios J, Gómez F, Pérez N, et al. Accuracy of the diagnosis of allergic reactions in the emergency department. J Investig Allergol Clin Immunol 2019; 29(3): 220-30.
[http://dx.doi.org/10.18176/jiaci.0313] [PMID: 30183657]
[154]
Blanca M, Mayorga C, Torres MJ, et al. Side-chain-specific reactions to betalactams: 14 years later. Clin Exp Allergy 2002; 32(2): 192-7.
[http://dx.doi.org/10.1046/j.1365-2222.2002.01299.x] [PMID: 11929481]
[155]
Torres MJ, Blanca M. The complex clinical picture of β-lactam hypersensitivity: Penicillins, cephalosporins, monobactams, carbapenems, and clavams. Med Clin North Am 2010; 94(4): 805-20.
[http://dx.doi.org/10.1016/j.mcna.2010.04.006] [PMID: 20609864]
[156]
Blumenthal KG, Shenoy ES, Huang M, et al. The impact of reporting a prior penicillin allergy on the treatment of methicillin-sensitive staphylococcus aureus bacteremia. PLoS One 2016; 11(7): e0159406.
[http://dx.doi.org/10.1371/journal.pone.0159406]
[157]
Picard M, Bégin P, Bouchard H, et al. Treatment of patients with a history of penicillin allergy in a large tertiary-care academic hospital. J Allergy Clin Immunol Pract 2013; 1(3): 252-7.
[http://dx.doi.org/10.1016/j.jaip.2013.01.006] [PMID: 24565481]
[158]
Macy E, Ngor EW. Safely diagnosing clinically significant penicillin allergy using only penicilloyl-poly-lysine, penicillin, and oral amoxicillin. J Allergy Clin Immunol Pract 2013; 1(3): 258-63.
[http://dx.doi.org/10.1016/j.jaip.2013.02.002] [PMID: 24565482]
[159]
Sastre J, Manso L, Sanchez-García S, Fernández-Nieto M. Medical and economic impact of misdiagnosis of drug hypersensitivity in hospitalized patients. J Allergy Clin Immunol 2012; 129(2): 566-7.
[http://dx.doi.org/10.1016/j.jaci.2011.09.028] [PMID: 22035657]
[160]
Mattingly TJ II, Fulton A, Lumish RA, et al. The cost of self-reported penicillin allergy: A systematic review. J Allergy Clin Immunol Pract 2018; 6(5): 1649-1654.e4.
[http://dx.doi.org/10.1016/j.jaip.2017.12.033] [PMID: 29355644]
[161]
Doña I, Moreno E, Pérez-Sánchez N, Andreu I, Hernández Fernandez de Rojas D, Torres MJ. Update on quinolone allergy. Curr Allergy Asthma Rep 2017; 17(8): 56.
[http://dx.doi.org/10.1007/s11882-017-0725-y] [PMID: 28752367]
[162]
King EA, Challa S, Curtin P, Bielory L. Penicillin skin testing in hospitalized patients with β-lactam allergies. Ann Allergy Asthma Immunol 2016; 117(1): 67-71.
[http://dx.doi.org/10.1016/j.anai.2016.04.021] [PMID: 27211057]
[163]
MacFadden DR, LaDelfa A, Leen J, et al. Impact of reported beta-lactam allergy on inpatient outcomes: A multicenter prospective cohort study. Clin Infect Dis 2016; 63(7): 904-10.
[http://dx.doi.org/10.1093/cid/ciw462] [PMID: 27402820]
[164]
Sakoulas G, Eckburg PB, Manley A, et al. 110. Clinical outcomes of patients with secondary bacteremia in the omadacycline phase 3 acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia studies. Open Forum Infect Dis 2019; 6 (Suppl. 2): S86-7.
[http://dx.doi.org/10.1093/ofid/ofz360.185]
[165]
Trubiano JA, Thursky KA, Stewardson AJ, et al. Impact of an integrated antibiotic allergy testing program on antimicrobial stewardship: A multicenter evaluation. Clin Infect Dis 2017; 65(1): 166-74.
[http://dx.doi.org/10.1093/cid/cix244] [PMID: 28520865]
[166]
Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64(4): 465-74.
[http://dx.doi.org/10.1002/acr.21596] [PMID: 22563589]
[167]
Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5(4): 309-16.
[http://dx.doi.org/10.1097/01.all.0000173785.81024.33] [PMID: 15985812]
[168]
Doña I, Gomez F, Salas M, et al. Patterns of response and drug involved in patients with multiple drug hypersensitivity syndrome. Clin Transl Allergy 2014; 4(S3): P138.
[http://dx.doi.org/10.1186/2045-7022-4-S3-P138]
[169]
Blumenthal KG, Lai KH, Huang M, Wallace ZS, Wickner PG, Zhou L. Adverse and hypersensitivity reactions to prescription nonsteroidal anti-inflammatory agents in a large health care system. J Allergy Clin Immunol Pract 2017; 5(3): 737-743.e3.
[http://dx.doi.org/10.1016/j.jaip.2016.12.006] [PMID: 28110055]
[170]
Li L, Chang Y, Song S, Losina E, Costenbader KH, Laidlaw TM. Impact of reported NSAID “allergies” on opioid use disorder in back pain. J Allergy Clin Immunol 2021; 147(4): 1413-9.
[http://dx.doi.org/10.1016/j.jaci.2020.08.025] [PMID: 32916184]
[171]
Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain. JAMA 2018; 319(9): 872-82.
[http://dx.doi.org/10.1001/jama.2018.0899] [PMID: 29509867]
[172]
Licciardone JC, Gatchel RJ, Aryal S. Effects of opioids and nonsteroidal anti-inflammatory drugs on chronic low back pain and related measures: Results from the PRECISION pain research registry. Tex Med 2018; 114(10): e1.
[PMID: 30281768]
[173]
Weberschock TB, Müller SM, Boehncke S, Boehncke WH. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): A systematic structured review of the literature. Arch Dermatol Res 2007; 299(4): 169-75.
[http://dx.doi.org/10.1007/s00403-007-0757-6] [PMID: 17492455]
[174]
Asero R, Quaratino D. Cutaneous hypersensitivity to multiple NSAIDs: Never take tolerance to selective COX-2 inhibitors (COXIBs) for granted! Eur Ann Allergy Clin Immunol 2013; 45(1): 3-6.
[PMID: 23678553]
[175]
Viola M, Quaratino D, Gaeta F, et al. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005; 137(2): 145-50.
[http://dx.doi.org/10.1159/000085794] [PMID: 15897671]
[176]
Li L, Laidlaw T. Cross-reactivity and tolerability of celecoxib in adult patients with NSAID hypersensitivity. J Allergy Clin Immunol Pract 2019; 7(8): 2891-2893.e4.
[http://dx.doi.org/10.1016/j.jaip.2019.04.042] [PMID: 31100553]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy